DaAnGene

HPV
(16/18 genotypes) DNA Test (Real-Time PCR)

HPV (16/18 genotypes) DNA Test (Real-Time PCR) is used to qualitatively detect human papillomavirus (HPV) type 16 and type 18 deoxyribonucleic acid (DNA) in cervical exfoliated cells and genitourinary secretions specimens.

DA-TF/HPV-100 V1/1

CE NMPA FSC

FEATURES

Target 70% cervical cancer related genotype

HPV genome L1 variant region as the target area, specific primers designed for HPV 16/18 which cause at least 70% of cervical cancer cases.

Quality control

Regard human constant expressed housekeeping gene as internal control genes to monitor the whole procedure from specimen collection to DNA amplification.

Open platform

Be based on RT-PCR technology, compatible with mainstream types of PCR instruments

Simplicity

Detect HPV 16/18 and internal control within one tube

All-in-one

Combine extraction kit and PCR kit in one product

BACKGROUND

- Cervical cancer is the fourth most common cancer among women globally, with an estimated **604, 000** new cases and **342, 000** deaths in 2020.
- More than 95% of cervical cancer is due to the human papillomavirus (HPV). HPV may repeatedly infect people and gradually become chronic and pre-cancerous lesions.
- Two HPV types (16 and 18) cause at least 70% of cervical cancers and are responsible for 50% of high-grade cervical pre-cancers.
- Cervical cancer can be cured if diagnosed at an early stage and treated promptly. 70% of women should be screened with a high-performance test by 35 years of age according to the new Global strategy adopted by World Health Assembly.

Estimated age-standardized incidence rates (World) in 2020, cervix uteri, all ages



Data source: GLOBOCAN 2020
Graph production: IARC (http://gco.iarc.fr/today)
World Health Organization

World Health Organization

Source: World Health Organization[1] & CDC[2]

Reference: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
https://www.cdc.gov/cancer/cervical/basic_info/
https://gco.iarc.fr/today/online-analysis-map

SCREENING TEST OF CERVICAL CANCER

World Health Organization

To reach the 2030 targets of cervical cancer elimination, WHO now encourages countries to use HPV tests for cervical screening, including HPV DNA and HPV mRNA tests.

- HPV-DNA testing detects high-risk strains of HPV, which cause almost all cervical cancers.
- HPV mRNA detects HPV infections leading to cellular transformation.

Reference: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
https://www.who.int/news/item/12-04-2022-meeting-of-who-director-general-s-expert-group-on-cervical-cancer-elimination--19-april-2022

HPV PCR TESTING WORKFLOW



PARAMETER

Test principle	Qualitative real-time fluorescent PCR
Specimen type	Cervical exfoliated cells, genitourinary secretions
Specimen extraction method	Spin column (recommended)
Fluorescence channel	FAM (HPV16/18 gene detection)
	VIC/HEX (Internal reference gene detection)
LOD	1.0E+04 copies/reaction
Storage and shelf life	Nucleic acid extraction reagent: 18-25℃, 9 months
	Nucleic acid amplification reagent: -20±5℃, 9 months
	Proteinase K and Carrier RNA: -20±5℃, 9 months
Applicable Instruments	ABI Prism 7500, ABI Prism 7300, LightCycler 480
Certificate	NMPA, FSC, CE

MAIN COMPONENTS

Extraction	Amplification
	
Extraction kit (Spin column)	PCR kit

ORDER INFORMATION

Description	Cat. No.	Package
HPV(16/18 genotypes) DNA Test (Real-Time PCR)	DA0540	48 tests/kit

CONTACT US

Daan Gene Co., Ltd.

CHINA (Headquarters)

Add: No.19, Xiangshan Road, Science Park, High & New Technology Development District, Guangzhou, Guangdong, P.R. China
Tel.: +86-20-32068126
Fax: +86-20-32068352
Email: marketing@daangene.com

CANADA office

Add.: #413-4538 Kingsway, Burnaby, BC V5H 4T9, Canada
Tel.: +1604 451 7588
Fax: +604451.7587
Email: gbai@daangene.net

COLOMBIA office

Add.: Cl 93 No.16 46 of 702, Bogotá D.C.
Tel.: +57 3103940417
Email: alonso.zheng@daangene.net

Website: https://en.daangene.com/